Trial Profile
A Pilot Study of Exendin-4 in Alzheimer s Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 23 Jan 2018 Status changed from completed to discontinued.
- 19 Nov 2016 Status changed from recruiting to completed.
- 03 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.